FFA
XENE icon

Farther Finance Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Farther Finance Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.57K Sell
96
-120
-56% -$7.13K ﹤0.01% 5179
2026
Q2 		$13K Buy
216
+27
+14% +$1.5K ﹤0.01% 4262
2026
Q1 		$10.7K Sell
189
-869
-82% -$40K ﹤0.01% 4066
2025
Q4 		$47.4K Buy
1,058
+212
+25% +$8.9K ﹤0.01% 2860
2025
Q3 		$34K Buy
846
+62
+8% +$2.18K ﹤0.01% 2688
2025
Q2 		$24.5K Buy
+784
New +$25.6K ﹤0.01% 2548

Other funds holding XENE

WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Farther Finance Advisors's XENE Position: Q3 2026 in Review

Farther Finance Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 56% in Q3 2026, selling an estimated $7.13K and leaving 96 shares worth $3.57K. The position accounts for ﹤0.01% of the portfolio, ranked #5179.

Farther Finance Advisors first reported a position in XENE in Q2 2025 and has held it in 6 quarters since. The position peaked at $47.4K in Q4 2025. 5 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Farther Finance Advisors held 96 shares of Xenon Pharmaceuticals worth $3.57K as of Q3 2026.
  • Farther Finance Advisors sold 120 Xenon Pharmaceuticals shares in Q3 2026, an estimated $7.13K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5179 holding.
  • Farther Finance Advisors first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Farther Finance Advisors's Xenon Pharmaceuticals position peaked at $47.4K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.